EHA 2024 Insights: Impact of the IMROZ Study on Newly Diagnosed Multiple Myeloma

EP: 1.Latest Trends and Innovations in Multiple Myeloma Management at EHA 2024

Now Viewing

EP: 2.EHA 2024 Insights: Impact of the IMROZ Study on Newly Diagnosed Multiple Myeloma

EP: 3.PERSEUS Trial Findings at EHA 2024

EP: 4.Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024

EP: 5.EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma

EP: 6.EHA 2024 Highlights: Overcoming Challenges with Bispecific Antibodies in RRMM

EP: 7.Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch

Video content above is prompted by the following:

• Please discuss the data presented at the European Hematology Association 2024 (EHA 2024) Hybrid Congress on the IMROZ study of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) vs VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).
• Please provide your key takeaways from this study. How do the results of this study impact the treatment of patients with transplant-ineligible NDMM?